search button

Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer

  • Authors:
    • Huakang Tu
    • Jian Gu
    • Qing H. Meng
    • Jeri Kim
    • Sara Strom
    • John W. Davis
    • Yonggang He
    • Elizabeth A. Wagar
    • Timothy C. Thompson
    • Christopher J. Logothetis
    • Xifeng Wu

  • View Affiliations

  • Published online on: January 18, 2017     https://doi.org/10.3892/ol.2017.5616
  • Pages: 1949-1957
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Serum testosterone is a potential marker to distinguish between indolent and aggressive prostate cancer (PCa). The present study aimed to investigate whether low levels of total serum testosterone at diagnosis were associated with aggressive PCa and poor clinical outcomes. In total, 762 non‑Hispanic Caucasian men with previously untreated PCa were recruited from The University of Texas MD Anderson Cancer Center (Houston, TX, USA). Patients were categorized into three groups based on their total serum testosterone levels according to clinical guidelines [low (<230 ng/dl), intermediate (230‑350 ng/dl) and normal (>350 ng/dl)]. PCa aggressiveness (low‑, intermediate‑ or high‑risk, or metastatic) was compared using multinomial logistic regression. Rates of disease progression, mortality from any cause and PCa‑specific mortality were compared using the multivariate Cox proportional hazards model. Testosterone levels significantly decreased as PCa aggressiveness increased (P<0.001). Compared with the normal testosterone group, the low testosterone group had 2.9‑fold (OR, 2.92; 95% CI, 1.74‑4.90; P<0.001), 5.6‑fold (OR, 5.63; 95% CI, 3.14‑10.12; P<0.001) and 72.4‑fold (OR, 72.40; 95% CI, 20.89‑250.89; P<0.001) increased risks of having intermediate‑risk, high‑risk and metastatic PCa, respectively. Furthermore, low levels of testosterone were significantly associated with a 10.7‑fold (HR, 10.68; 95% CI, 1.35‑84.44; P=0.03) increased risk of PCa‑specific mortality. The results of the present study indicate that low levels of total serum testosterone at diagnosis are associated with aggressive PCa and predict poor PCa‑specific survival.
View Figures
View References

Related Articles

Journal Cover

March-2017
Volume 13 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Tu H, Gu J, Meng QH, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis C , Logothetis C , et al: Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol Lett 13: 1949-1957, 2017.
APA
Tu, H., Gu, J., Meng, Q.H., Kim, J., Strom, S., Davis, J.W. ... Wu, X. (2017). Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncology Letters, 13, 1949-1957. https://doi.org/10.3892/ol.2017.5616
MLA
Tu, H., Gu, J., Meng, Q. H., Kim, J., Strom, S., Davis, J. W., He, Y., Wagar, E. A., Thompson, T. C., Logothetis, C. ., Wu, X."Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer". Oncology Letters 13.3 (2017): 1949-1957.
Chicago
Tu, H., Gu, J., Meng, Q. H., Kim, J., Strom, S., Davis, J. W., He, Y., Wagar, E. A., Thompson, T. C., Logothetis, C. ., Wu, X."Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer". Oncology Letters 13, no. 3 (2017): 1949-1957. https://doi.org/10.3892/ol.2017.5616